BCM
CBAY

Bayesian Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Bayesian Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-67,400
Closed -$1M – 1087
2023
Q3 		$1M Buy
67,400
+28,500
+73% +$378K 0.11% 222
2023
Q2 		$426K Buy
+38,900
New +$362K 0.05% 449
2020
Q4 		– Sell
-22,400
Closed -$162K – 701
2020
Q3 		$162K Buy
+22,400
New +$120K 0.04% 458

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bayesian Capital Management's CBAY Position: Q4 2023 in Review

Bayesian Capital Management sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 67,400 shares — an estimated $1M sold.

Bayesian Capital Management first reported a position in CBAY in Q3 2020 and held it in 3 quarters. The position peaked at $1M in Q3 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

  • Bayesian Capital Management reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Bayesian Capital Management sold 67,400 Cymabay Therapeutics shares in Q4 2023, an estimated $1M.
  • Bayesian Capital Management first reported a position in Cymabay Therapeutics in Q3 2020 and held it in 3 quarters.
  • Bayesian Capital Management's Cymabay Therapeutics position peaked at $1M in Q3 2023.
  • 200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Bayesian Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.